Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company's two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
MYOVANT SCIENCES LTD. 
